Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection

Background During SARS-CoV-2 pandemic, the anticoagulant management in patients with atrial fibrillation (AF) was simplified to the use of low molecular weight heparin (LMWH) in different international guidelines. These recommendations were based for the possible drug interactions between oral antic...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivera, Pável E, Campoy, Desiree, Velasquez, César A, Flores, Katia, Canals, Tania, Johansson, Erik A, Martinez, Laia, Sierra, Jorge, Cerezo, Juan Jose, Salinas, Ramón
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2020
Materias:
332.Anticoagulation and Antithrombotic Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330256/
http://dx.doi.org/10.1182/blood-2020-143065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330256/
http://dx.doi.org/10.1182/blood-2020-143065

Ejemplares similares